Publication | Closed Access

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

Cell TherapyTransplantationGemtuzumab OzogamicinHepatic Veno-occlusive DiseaseStem Cell TransplantationHematologyImmunologyCell Replacement TherapyMedicineCell Transplantation